Both are proud they dodged the Twitter bullet. But, in retrospect, was it really a bullet?
A dividend hike and a big buyback authorization by Mr. Softee should produce value for shareholders.
The cloud stock's results weren't great, but were nothing close to the FedEx disaster.
After a sprint higher in the IT company's shares in recent days, traders and investors might do well to wait for a temporary pullback to pick up the stock.
Alexion Pharmaceuticals and Elanco Animal Health have seen their shares go to the dogs of late, but still offer reasons for portfolio consideration.
The cybersecurity name fired off some punches at the competition and picked up another bolt-on acquisition amid earnings.
Shares of the provider of network security platforms could bump into a resistance zone after a strong start.
Sure, Celgene, in its tie-up with Bristol-Myers Squibb, had to sell to meet merger requirements, but look at the future pay off for Amgen.
With total deals trending toward hundreds of billions, investors may be eager to bet on who's next to be acquired.
Amgen's deal to buy Otezla from Celgene should not deter the drugmaker's stock from gaining ground over the long haul.